Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder Cancer
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Our series of 195 patients, plus 134 reported on in the literature and 949 reviewed by various physicians provide 1,278 patients for review of bacillus Calmette-Guerin therapy complications. Cystitis occurred in 91 per cent of the patients. Complications identified included fever more than 103F in 50 patients (3.9 per cent), granulomatous prostatitis in 17 (1.3 per cent), bacillus Calmette-Guerin pneumonitis or hepatitis in 12 (0.9 per cent), arthritis or arthralgia in 6 (0.5 per cent), hematuria requiring catheterization or transfusion in 6 (0.5 per cent), skin rash in 5 (0.4 per cent), skin abscess in 5 (0.4 per cent), ureteral obstruction in 4 (0.3 per cent), epididymo-orchitis in 2 (0.2 per cent), bladder contracture in 2 (0.2 per cent), hypotension in 1 (0.1 per cent) and cytopenia in 1 (0.1 per cent). Most of the severe irritative side effects and subsequent systemic complications can be prevented with prophylactic isoniazid given for 3 days, beginning the morning of treatment. Patients with life-threatening systemic bacillus Calmette-Guerin infection or anaphylaxis should receive 500 mg. cycloserine twice daily for 3 days in addition to combination antituberculous therapy because the rapid action of this drug may be life-saving. Direct intralesional bacillus Calmette-Guerin immunotherapy can produce sepsis and death, and should be avoided but intravesical bacillus Calmette-Guerin generally is well tolerated and has produced no complication in more than 95 per cent of the patients treated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tolerability profile of intravesical BCG therapy is generally favorable, with minor and transient adverse effects occurring in 10-50% of patients.”
Citations
Cites
Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder Carcinoma
Brosman, S. A. (1982) · Journal of Urology · doi:10.1016/s0022-5347(17)52736-6 · Cited by 314
Lötte, A., WASZ‐HÖCKERT, O., Poisson, N., Dumitrescu, N., Verron, M., & Couvet, E. (1984) · PubMed · Cited by 294
Lötte, A. (1984) · Medical Entomology and Zoology · Cited by 200
Zincke, H., Utz, D. C., Taylor, W. F., Myers, R. P., & Leary, F. J. (1983) · The Journal of Urology · doi:10.1016/s0022-5347(17)52205-3 · Cited by 126
Nonspecific Immunotherapy with BCG Vaccine in Bladder Tumors
Martinez-Piñeiro, J. A., & Muntañola, P. (1977) · European Urology · doi:10.1159/000472047 · Cited by 57
Bladder Tumors and other Topics in Urological Oncology
Pavone-Macaluso, M., Smith, P. H., & Edsmyr, F. (1980) · Springer eBooks · doi:10.1007/978-1-4613-3030-1 · Cited by 56
Intradermal BCG vaccination complications— Analysis of 51 cases
de Souza, G. R. M., Sant’Anna, C. C., Silva, J. R. L. E., Mano, D. B., & Bethlem, N. M. (1983) · Tubercle · doi:10.1016/0041-3879(83)90046-6 · Cited by 56
A Comparison of Treatment Methods for the Prophylaxis of Recurrent Superficial Bladder Tumors
Netto, N. R., & Lemos, G. C. (1983) · The Journal of Urology · doi:10.1016/s0022-5347(17)51905-9 · Cited by 34
Douville, Y., Pelouze, G., Roy, R., Charrois, R., Kibrité, A., Martín, M., Dionne, L., Coulonval, L., & Robinson, J. (1978) · PubMed · Cited by 27
[Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
Flamm, J., & Grof, F. (1981) · PubMed · Cited by 12
Research works printed but not linked: 3
- Zincke, 1984, Tumor recurrence after intravesical instillation of thio-tepa (TT) and mitomycin C (MC) at time of transurethral resection of bladder cancer (TaTcis) and postoperatively, J. Urol., 131, 138A
- Stober, 1980, BCG Immunotherapy zur Rezidivprophylaxe beim har Blasenkarzinom, Therapiewoch, 30, 6067
- Flamm, 1981, Adjuvante lokale Immunotherapie mit bacillus Calmette-Guerin (BCG) in der Behandlung des Urothelkarzinoms der Harnblase, Wien. Med. Wochenschr., 131, 501
Cited by
SYLVESTER, R. J., van der MEIJDEN, A. P. M., & LAMM, D. L. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64273-5 · Cited by 1,312
Self-citationLamm, D. L., Van Der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., Soloway, M. S., Steg, A., & Debruyne, F. M. J. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37316-0 · Cited by 786
Self-citationShelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02306.x · Cited by 313
Spectrum of Bacille Calmette‐Guerin (BCG) Infection after Intravesical BCG Immunotherapy
Gonzalez, O. Y., Musher, D. M., Brar, I., Furgeson, S., Boktour, M. R., Septimus, E. J., Hamill, R. J., & Graviss, E. A. (2003) · Clinical Infectious Diseases · doi:10.1086/344908 · Cited by 195
Martínez Piñeiro, J. A., León, J. J., Martínez Piñeiro, L., Fiter, L., Mosteiro, J. A., Navarro, J., García Matres, M. J., & Cárcamo, P. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40002-4 · Cited by 178
Metadata
- Authors
- Lamm, D. L., Stogdill, V. D., Stogdill, B. J., & Crispen, R. G.
- ORCID
- Lamm, Donald L.
- Venue
- Journal of Urology
- Published
- 1986-02
- Volume
- 135
- Issue
- 2
- Pages
- 272-274
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2414380551
- Cited by
- 394
- References
- 10
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 4 · 2018: 9 · 2017: 5 · 2016: 4 · 2015: 17 · 2014: 7 · 2013: 7 · 2012: 10
- FWCI
- 29.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- BCG vaccine, BCG immunotherapy, bladder cancer, treatment complications, cystitis, fever, granulomatous prostatitis, pneumonitis, hepatitis, isoniazid preventive therapy, cycloserine, anaphylaxis, sepsis, hematuria, epididymo-orchitis
- MeSH terms
- Biological Products, Urinary Bladder Neoplasms, Combined Modality Therapy, Cycloserine, Female, Humans, Immunotherapy, Isoniazid, Male, Mycobacterium bovis, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.